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Abstract 
A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and described, particularly 
in the last decade. This continually expanding array of bnAbs has crucially led to the identification of novel epitopes 
on the HIV envelope protein via which antibodies can block a broad range of HIV strains. Moreover, these studies 
have produced high-resolution understanding of these sites of vulnerability on the envelope protein. They have also 
clarified the mechanisms of action of bnAbs and provided detailed descriptions of B cell ontogenies from which they 
arise. However, it is still not possible to predict which HIV-infected individuals will go onto develop breath nor is it 
possible to induce neutralization breadth by immunization in humans. This review aims to discuss the major insights 
gained so far and also to evaluate the requirement to continue isolating and characterizing new bnAbs. While new 
epitopes may remain to be uncovered, a clearer probable benefit of further bnAb characterization is a greater under-
standing of key decision points in bnAb development within the anti-HIV immune response. This in turn may lead to 
new insights into how to trigger bnAbs by immunization and more clearly define the challenges to using bnAbs as 
therapeutic agents.
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Background
HIV infection remains a major global health challenge 
but to date, it has not been possible to induce protec-
tive immunity against this virus by vaccination. This 
is different to the situation with other viral pathogens, 
such as measles, where the immune response triggered 
by vaccines, specifically the antibodies induced provide 
complete protection from disease. In contrast, antibod-
ies induced by both natural HIV infection and vaccine 
candidates generally are not of sufficient quality to pro-
tect from infection. This is largely because they are highly 
specific for the distinct strain of HIV to which the indi-
vidual was exposed, or even specific for a just a small 
proportion of the intra-patient quasi-species in the case 
of an infected individual. Furthermore, the viral protein 
they bind, the envelope glycoprotein (Env), is expressed 
at a low level on the viral surface in a unstable conforma-
tional state. Therefore, it is challenging for the immune 
system to produce effective antibodies against HIV most 
antibodies. Thus, they cannot prevent infection by circu-
lating HIV strains in the general population. However, 
in a rare subset of HIV-infected individuals antibodies 
arise that are able to recognize and block an extremely 
wide array of HIV strains. These are known as broadly 
neutralizing antibodies (bnAbs) and are so highly func-
tional due to a combination of extensive somatic hyper-
mutation and unusual structural features, notably very 
long complementarity determining region (CDR3) loops. 
Since 2009 the identification of a huge number of bnAbs 
has provided new impetus for HIV vaccine research. This 
review will explore what has been learnt from this renais-
sance in HIV antibody research, what remains to be 
understood and crucially whether we need to continue to 
isolate HIV bnAbs given the exponential discovery rate of 
these remarkable antibodies over the last decade.
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Why study bnAbs against HIV?
Shortly after the identification of HIV as the causative 
agent of AIDS it became clear that antibody responses in 
infected patients were mainly limited to neutralizing only 
HIV strains closely related to the infecting virus [1–3]. 
This raised the idea that the induction of bnAbs would 
be a necessary step in the development of a protective 
HIV vaccine. However, some years elapsed before the 
description of the first monoclonal antibody (mAb) with 
the capability to neutralize divergent HIV strains [4]. This 
discovery demonstrated that the human immune system 
could indeed produce such highly functional antibodies. 
This mAb, b12, was followed by a handful of additional 
bnAbs (4E10, 2F5, 2G12). These discoveries were cru-
cial conceptually, in that they demonstrated clearly that 
antibodies can block in  vitro infection by a wide-range 
of HIV strains and are not always limited by strain-
dependent differences. Moreover, the isolation of these 
bnAbs facilitated landmark in  vivo experiments which 
showed that it is possible to protect animals from infec-
tion via both high-dose and repeated low-dose challenge 
[5–10]. This demonstrated the principle that the presence 
of bnAbs at a systemic level can prevent infection and 
provided an immunological benchmark to aim for dur-
ing vaccination studies. The isolation of additional bnAbs 
in the last decade has confirmed the potential of passive 
transfer of these antibodies. Many of the new bnAbs have 
significantly improved potency and this is reflected by 
the smaller doses required to protect from infection [11] 
and that protection can be achieved even with bnAbs that 
result in incomplete neutralization at low concentrations 
in  vitro [12]. Moreover, recently it has been seen that a 
single dose of a bnAb can protect from repeated infec-
tious challenge [13] and that dosing after infection can 
result in a degree of virological control [14, 120]. Thus, 
the stage is now set for the adaption of bnAbs for use as 
therapeutic/prophylactic agents in humans. In turn, this 
progress raises the central question of this review: are 
there now enough HIV bnAbs? To address this, it is first 
necessary to consider what information has been learnt 
so far from studying bnAbs and what insights this has 
provided.
The most fundamental information gained from the 
studying of bnAbs since the isolation of b12 has been 
the definition of bnAb binding sites on HIV Env. Spe-
cifically in terms of the limits they impose on anti-
body binding which render them challenging targets 
to hit by vaccination. The five key bnAb epitopes are 
the CD4 host receptor-binding site (CD4bs), the high 
mannose patch, the Env trimer apex, the membrane 
proximal region (MPER) and the subunit interface 
region between the gp120 and gp41 subunits of Env 
(Fig.  1). Of these, the CD4bs, MPER and high man-
nose patch were identified by bnAbs first described 
in the 1990s/early 2000s. However, the exponential 
growth in bnAb identification since 2009 has provided 
great insight into the biology of HIV Env, including 
Fig. 1 Continual advances in identifying bnAb epitopes on HIV Env 
following the identification of new bnAbs. Each panel represents 
a key advance in the identification of new epitopes/refinement of 
epitopes bound by bnAbs. The Env figure is adapted from the crystal 
structure of the BG505 SOSIP.664 trimer (PDB: 5cez), gp120 is coloured 
light grey, gp41 is coloured dark grey. Approximate epitope locations 
are indicated by red arrows/lines and circles are color-coded for each 
year as shown in the key given in each panel heading. Epitopes are 
highlighted only once per protomer. a Pre 2009 knowledge of CD4bs, 
glycan and MPER epitopes gained from studying predominantly 
by b12, 2G12, 2F5 and 4E10 respectively. b By 2010 the trimer apex 
epitope had been described following discovery of PG9/16 in 2009 
and the importance of angle of approach to the CD4bs highlighted 
by the discovery of VRC01 in 2010. c The glycan patch epitope 
was redefined as supersite of vulnerability by the isolation of the 
PGT121 and 128 families of bnAbs in 2011. d From 2014 onwards 
the discovery of additional bnAbs, including PGT151, 35O22 and 
8ANC195, revealed a new area of bnAbs which span the gp120–gp41 
interface. e In 2016 subunit interface targeting antibodies were found 
that also bind the gp41 fusion peptide, VRC34 and ACS202. f 2018 
saw the description of bnAbs binding the highly glycosylated “silent” 
face of gp120 and targeting CD4bs via novel contacts with the gp120 
inner domain after bypassing the Phe43 cavity
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the definition of two new major  bnAb binding sites 
(the apex and interface) as illustrated in Fig.  1. Thus, 
the expanding array of HIV bnAbs continue to re-
define our molecular understanding of the neutraliz-
ing epitopes on Env and the challenges associated to 
inducing bnAbs by vaccination.
Insights into HIV Env: CD4bs
A logical mode of action for an HIV bnAb is to inter-
fere with the binding of HIV, via Env, to the human host 
receptor protein CD4. Not only because it is a crucial 
step in viral entry but also because the high variability of 
HIV Env is constrained in the CD4bs as certain features 
must be conserved to maintain the interaction with the 
host receptor. Indeed, the earliest described bnAb, b12, 
binds to the CD4bs of Env [4]. However, the viral entry 
process facilitated by the interaction between Env and 
CD4 is complex and involves multiple conformational 
changes within the viral protein. This became apparent 
early on from studies comparing b12 with other mAbs 
that target the CD4bs but are not able to neutralize pri-
mary HIV isolates in  vitro [15] nor provide protection 
from infection after passive transfer [16]. Studies with 
the gp120 subunit of Env revealed that the molecular 
contacts of non-neutralizing CD4bs antibodies differ 
from those of neutralizing CD4bs antibodies [17]. Subse-
quently cryo-electron microscopy has confirmed that the 
non-neutralizing CD4bs antibodies bind to an opened-
up form of the Env gp120–gp41 trimer not the tightly-
associated trimer which is needed to engage CD4 and 
enable infection [18]. Understanding of the CD4bs bnAb 
epitope has accelerated rapidly since the description of 
the second CD4bs bnAb VRC01 in 2010 [19]. This bnAb 
and its clonal variants disproved the notion that the best 
possible CD4bs bnAb would closely mimic human CD4. 
Instead of mimicking CD4, VRC01, which neutralizes 
~80% of HIV strains as opposed to the ~ 40% neutral-
ized by b12, binds at a 45 °C angle relative to the orien-
tation of CD4 binding to Env [19]. This preferred angle 
of approach for CD4bs bnAbs has proven to be a gen-
eral requirement, not only in the vast family of VRC01 
variants [20] but also in genetically distinct bnAbs [21]. 
A precise binding angle is needed to enable the bulky 
fab fragment of the bnAb to enter the CD4bs, which is 
recessed in what can be termed a canyon on the surface 
of Env. Recessed host receptor binding sites are a  fre-
quent feature of pathogens, for example polio virus, as 
this can limit recognition by the host antibody responses 
[22, 23]. That HIV utilizes a similar mechanism was pre-
dictable from early structural studies of CD4 binding to 
Env. However, it was the isolation of a large number of 
CD4bs BnAbs, all binding at similar angles, that proved 
this was a major challenge for inducing antibodies 
against this site. Furthermore, in-depth study of CD4bs 
bnAbs has defined an epitope signature of molecular 
contacts that  this class of bnAbs use to bind Env [24] 
Such extensive characterization of CD4bs bnAbs has also 
revealed that HIV adds to the geometric obstacle posed 
by the location of the CD4bs by presenting a high level of 
amino acid diversity around the entrance to the canyon. 
The blocking effect this achieves is amplified by post-
translational modifications, namely N-linked glycosyla-
tion. Specifically, the presence of N-linked glycans close 
to the CD4bs can be highly obstructive, and there is some 
evidence they limit the binding of CD4bs bnAb precur-
sors, thus impeding the development of mature CD4bs 
bnAbs [25]. Despite the intrinsic challenge in target-
ing the CD4bs many bnAbs against this site continue to 
arise during natural infection. Recently, a CD4bs bnAb, 
N6, was identified that is even more potent and described 
as displaying near-pan neutralization breadth [26] and 
has been found to suppress plasma viral loads in a non-
human primate model [14]. Moreover, new methods for 
bnAb identification continue to emerge as illustrated 
by the description of another CD4bs bnAb N49P7 [27]. 
This antibody was identified directly from plasma using 
proteomics and antibody lineage analysis. Importantly, 
N49P7 binds the CD4bs in a new fashion, bypassing the 
Phe43 cavity and instead contacting the inner domain of 
gp120 [27].
Insights into HIV Env: high mannose patch
One of the most unusual and intriguing early bnAbs 
was 2G12 [28]. This unusual domain-swapped antibody 
directly recognizes N-linked glycans close to the third 
variable loop (V3) of gp120. The sugar moieties covering 
Env are unlike bacterial polysaccharides, which are well-
recognized by the human antibody response and form 
the basis for some preventative vaccines. The N-linked 
polysaccharides which comprise approximately 45% of 
the total mass of Env are fundamentally human in ori-
gin. This is because Env is produced in host cells and 
undergoes post-translation modification with human gly-
can processing enzymes. Therefore, these structures are 
largely tolerated by the immune system and minimally 
immunogenic. This explains the observation that intra-
patient viral quasi species gain more potential N-linked 
glycan sites (PNGS) over time and that this is associated 
with a loss of serum neutralization activity, as the neu-
tralization epitopes are hidden by the extra glycans [29, 
30]. However, the joint presentation of N-linked glycans 
with viral protein at an unusually high density on cer-
tain parts of Env can be recognized by human antibod-
ies. Until 2011 the only well-defined glycan-specific bnAb 
was 2G12 and attempts to re-elicit such specificities had 
induced glycan-specific antibodies but they were not able 
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to neutralize HIV [31]. The description of the PGT121 
and PGT128 bnAb families in 2011 demonstrated that 
reactivity with this dense patch of mainly high mannose 
glycans is not solely possible with a domain swapped 
antibody [32]. On the contrary, this specificity is one of 
the most commonly found in patients with bnAb activity 
in their sera [33, 34]. This is a striking observation given 
the minimally-immunogenic nature of N-linked glycans 
in humans, and the observations that HIV uses the hosts’ 
sugars to create a glycan shield to hide behind [29]. It 
suggests that in chronic HIV infection, the pressure on 
the humoral immune system to halt the virus is strong 
enough to make even N-linked host glycans a viable tar-
get. On a molecular and structural level, the study of the 
PGT121 and 128 families revealed a particular glycan, 
which alternates between position N332 or N334 within 
Env, was a key lynch pin for binding and neutralization 
by this class of bnAb [32]. Isolation of additional clonal 
variants and unrelated bnAbs targeting the same site led 
to structural comparison studies which highlighted the 
divergent modes of recognition and angles of approach 
possible for these BnAbs [35, 36], which is a stark con-
trast to CD4bs bnAbs. This high mannose site has thus 
been termed a supersite of vulnerability and recent work 
has shown that separate bnAb families against this site 
can arise within the same individual [37]. That there are 
so many structural and genetically diverse ways for anti-
bodies to target the high mannose site has led to renewed 
efforts to design vaccine candidates to induce such anti-
bodies [38, 39]. Moreover, high mannose patch specific 
bnAbs including PGT121 and 10-1074, have shown great 
promise in passive transfer studies both in regard to pre-
venting infection at low doses [11] and controlling estab-
lished infection [14, 120]. Notably, data in these studies 
do highlight the risk of escape mutations if bnAbs are 
used as monotherapy. While this will undoubtedly hold 
true for all specificities, intensive study of individual 
glycan-patch specific bnAbs has shown that if the loss 
of the N332/N334 glycan does not enable escape, HIV 
will escape sometime by unusual mutations such as the 
introduction of disulfide bonds [40, 41]. In addition to 
highlighting how the virus can escape from antibodies, 
such detailed studies of individual high-mannose patch 
bnAbs have also suggested reasons why mechanistically 
this particular part of the glycan shield is a good bnAb 
epitope. Namely, that it includes a motif that is associated 
to CCR5 co-receptor binding [42] and thus it is a key part 
of the viral entry process.
Insights into HIV Env: MPER
The MPER is another example of a bnAb epitope that was 
originally described before the recent wave of HIV bnAb 
isolation. However, since 2009 only one additional MPER 
bnAb, 10E8, has been studied in great detail [43]. Regard-
less, characterization of 10E8, alongside new studies with 
previously described MPER bnAbs, have provided valu-
able insight. Namely, that there have been refinements in 
our molecular [44, 45] and structural understanding of 
how this epitope is recognized [46, 47] and the particular 
obstacles faced when attempting to elicit MPER bnAbs 
following vaccination. The original MPER bnAbs, 2F5 
and 4E10, bind to an overlapping linear epitope in the 
gp41 subunit. The movement of gp41 is a key step dur-
ing viral fusion, thus as per the CD4bs, the location of 
MPER itself suggests why these antibodies can effectively 
prevent infection. Moreover, recent work has shown that 
10E8 can actually destabilize the Env trimer which the 
authors describe as a novel mechanism of neutraliza-
tion [48]. MPER is highly conserved across HIV strains 
and as a result this class of bnAbs have the potential for 
great breadth, as seen with 4E10 [49] and also potency, 
with both attributes combined in 10E8 [43]. This new 
MPER bnAb has also been shown to protect non-human 
primates from infectious challenge [50]. All of this makes 
MPER an attractive target for vaccine design, particu-
larly as a linear epitope is easier to manipulate than a 
conformational epitope and many different approaches 
have been explored to present the MPER peptide to the 
immune system [51]. However, detailed characterization 
of the binding of 2F5, 4E10, and more recently 10E8, has 
shown that the MPER bnAb epitope is complicated by 
its proximity to the viral membrane and that neutraliza-
tion is achieved in part via lipid binding as reviewed in 
[52]. This suggests that the MPER epitope needs to be 
presented in the context of lipid to induce neutralizing 
antibodies. The flipside to this is that lipid-reactive anti-
bodies, like N-glycan reactive antibodies, are essentially 
binding to a host component. Indeed, it was initially 
shown that this potential for autoreactivity negatively 
regulates the development of 4E10-expressing B cells in 
transgenic knock in mice [53]. More recently, deletion 
of 2F5-expressing B cells has been observed in knock-
in mice [54]. Macaques immunized with a 2F5-tailored 
immunogen did make 2F5-like B cell clonal lineages but 
with insufficient affinity to neutralize virus [54]. The 
authors suggest this is because gp41 bnAbs are limited 
by immune tolerance mechanisms against lipid binding. 
The authors further propose that vaccination will require 
intervention to overcome immunological tolerance [54] 
as reviewed in [55]. Notably MPER bnAbs are found dur-
ing natural infection, despite the blocks to the develop-
ment of these bnAbs seen thus far in animal models. This 
contrast in MPER-specific B cell fate is most starkly seen 
in a recent study showing that B cells producing MPER 
bnAbs can differentiate into both peripheral memory B 
cells and long-lived bone marrow plasma cells in  vivo 
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[56]. Moreover, in this particular HIV-positive individual, 
the inferred common ancestor of the entire MPER bnAb 
family was found to be autoreactive, which supports 
the argument that tolerance needs to be compromised 
for MPER bnAb development [56]. However, a separate 
study showed vaccination could induce long-lived bone 
marrow plasma cells that produce MPER antibodies that 
aren’t autoreactive, although notably they were also not 
bnAbs [57]. Thus, there remains debate about the limits 
imposed by immunological tolerance in the development 
of bnAbs, particularly against MPER.
Insights into HIV Env: trimer apex
Arguably, the identification of new epitopes has been 
the most significant output from the characterization 
of HIV bnAbs over the last decade. The first new bnAb 
epitope described was that bound by PG9 and PG16, a 
pair of somatic variant antibodies, which were the first 
in the new wave of bnAbs [58]. Crucially the identifica-
tion of novel epitopes was made possible by using an 
unbiased selection method as reviewed in [59]. The land-
mark study by Walker et al. [58] showed that these anti-
bodies recognized a highly conserved epitope centered 
on an N-linked glycan at N160, which is preferentially 
expressed on trimeric Env and spans conserved regions 
of first and second variable loops (V1/V2) of the gp120 
subunit. Structural studies revealed that PG9/16 bind in a 
heavy chain dominated fashion, using a long third heavy 
chain complementarity determining region (CDRH3) in 
what was termed a “hammerhead” structure to bind to 
the V1/V2 at the very top of the Env trimer where the 
three gp120 subunits meet to form the trimer apex [60]. 
Later work redefined the precise molecular requirements 
of the apex class of bnAbs, including PG9/16 along-
side other bnAbs, and the contribution to the paratope 
made by bnAb framework regions [61]. Furthermore, 
additional structural studies on the PGT145 apex bnAb 
[58] confirmed previous work on the trimeric nature of 
this epitope by demonstrating the CDRH3 penetrates 
between glycans at the trimer threefold axis, to contact 
peptide residues from all three Env protomers [62]. In 
addition, a novel apex bnAb, BG1, was observed to bind 
asymmetrically to Env using a compact CDRH3 rather 
than a hammerhead structure [63]. Thus, this bnAb binds 
in a 2:1 ratio to Env trimer, rather than 1:1 as per classical 
apex bnAbs such as PG9 [63].
Similar to the high-mannose patch bnAbs, apex bnAbs 
not only successfully navigate around the glycan shield 
of Env but also bind directly to N-linked glycans. The 
original description of PG9/16 highlighted the crucial 
importance of the N160 glycan in particular for this class 
of bnAbs [58]. More recently, in depth analysis of pre-
cursor antibodies of another apex bnAb, VRC26, have 
shown a preference for sialic acid-bearing glycans [64]. 
This work also highlighted that binding to these glycans 
served as an “anchor” for the nascent bnAb, regardless 
of amino acid variation in the epitope. Thus rendering 
the antibody lineage resistant to complete neutralization 
escape and allowing the eventual development of breadth 
[64]. As discussed above, the utilization of N-linked gly-
cans by apex and high-mannose patch bnAbs is at odds 
with the observations on the immunosuppressive nature 
of Env glycans. Namely, that “holes” in the glycan shield 
are highly susceptible targets for immunization-induced 
neutralization [65] and that adding glycans to Env hides 
neutralizing epitopes from the immune system [29]. So 
the observation that these two classes of bnAbs recognize 
these generally non-immunogenic structures suggests 
that the regulation of the cells producing them has been 
altered in some way, perhaps also involving alterations 
in tolerance as suggested for MPER bnAbs. An alterna-
tive explanation for N-glycan reactivity is that the par-
ticular sugars eliciting bnAbs are altered in some way in 
comparison to glycans on host proteins. This idea is sug-
gested by work showing very high avidity binding of PG9 
to synthetic hybrid glycans, which led the authors to pro-
pose that these unusual sugars may have been the origi-
nal ligand for the PG9 bnAb family [66].
Insights into HIV Env: gp120–gp41 interface
The trimer apex is not the only new bnAb epitope to have 
been identified by the isolation of new bnAbs. The iso-
lation of PGT151 [67] defined the interface between the 
gp120 and gp41 subunits as an area targeted by bnAbs. 
Notably, this novel specificity was also identified by the 
unbiased selection of a bnAb for neutralization activ-
ity rather than using proteins presenting known bnAb 
epitopes as reviewed in [59]. One of the unique features 
of this first-in-class interface bnAb is its requirement for 
complete cleavage of the subunits prior to trimer assem-
bly [68]. This meant that much of the original characteri-
zation was performed with cell-surface Env derived from 
the JRFL strain as available soluble Env proteins were not 
adequate mimics of the interface site [67]. As highlighted 
above, rearrangement of the Env subunits is a crucial part 
of the viral entry process and so a logical target for a neu-
tralizing antibody. Moreover, there is a level of conserva-
tion in this region across viral strains, due to the need to 
maintain the correct oligomeric structure. However, the 
subunit interface had not previously been considered as a 
bnAb target, in part due to the predominant experimen-
tal use of separate gp120 and gp41 proteins. This tech-
nical limitation has been overcome in the last decade 
by the development of native-like Env trimers [69–72]. 
The development of new trimers and the characteriza-
tion of interface bnAbs have been mutually beneficial, 
Page 6 of 12McCoy  Retrovirology  (2018) 15:70 
with PGT151 in particular being of great use to exclu-
sively purify properly cleaved trimers by affinity chroma-
tography [73]. The same holds true for the apex bnAbs, 
which can be used to select for tightly folded recombi-
nant trimer [73–75]. Another similarity is that PGT151 
also recognizes N-linked glycans as part of its epitope, 
although in this case it requires the loss of two separate 
glycans to destroy the epitope and prevent neutralization 
[67].
Simultaneous with the description of PGT151 addi-
tional bnAbs were found to target the subunit interface 
region of vulnerability but each via distinctive Env con-
tact sites. Notably, many were also identified by a neu-
tralization based selection method, including 35O22 [76]. 
Interestingly, 35O22 is derived from the same source 
individual as the MPER bnAb 10E8. 35O22 like PGT151 
is trimer specific, but it is different in that can bind both 
cleaved and uncleaved forms of Env. Another similar-
ity between these interface bnAbs is that the removal of 
specific glycans from Env decreases their neutralization 
activity. Namely, N88, N230, N241 and N625 in the case 
of 35O22 [76]. Furthermore, for particular viruses, both 
bnAbs can achieve only 50–80% neutralization even at 
very high concentration of antibody. This incomplete 
neutralization phenomenon has been observed with all 
classes of bnAbs and is due to resistance in a fraction 
of the virus population arising due to glycan and possi-
bly conformational heterogeneity [77, 78]. Thus, study 
of interface bnAbs has highlighted the extensive post-
translational variation in any given population of HIV 
virions and the challenge this poses to preventing infec-
tion. 35O22 also gave rise to greater insight into the 
fusion process required for HIV entry. Previously, it was 
shown the MPER bnAbs bind more efficiently after the 
conformational changes induced by CD4 engagement 
[79]. 35O22 was also observed to bind poorly to mem-
brane-bound Env prior to CD4 engagement and to prefer 
an early intermediate conformation during fusion. The 
authors speculated that this could be because the Env is 
raised within the viral membrane at the start of fusion 
that leads to greater exposure of the 35O22 epitope 
[76]. Notably, another of the interface bnAbs, 8ANC195 
[80], actually alters the conformation of Env by induc-
ing a partially closed form of the CD4-bound trimer [81]. 
Thus, characterization of 8ANC195, confirmed that Env 
exhibits a high level of conformational heterogeneity and 
revealed a previously unseen conformation. It is impor-
tant to note that this is the highly diverse class of interface 
bnAbs, which bind a common area on the trimer rather 
than closely overlapping epitopes as is the case with the 
other classes discussed above. For example, two new 
bnAbs (ACS202 and VRC34) have been described which 
target the interface area but actually crucially interact 
with the Env fusion peptide [82, 83]. ACS202 and VRC34 
bnAbs also exhibit common interface bnAb features such 
as a requirement for trimeric Env and including N-linked 
glycans within their epitope. Recently another interface 
bnAb, named CAP248-2B, similar to PGT151, was iden-
tified which, like PGT151, also partly binds via the fusion 
peptide [84]. Intriguingly, mutations that abrogate the 
neutralization of CAP248-2B actually increase the sus-
ceptibility of the virus to neutralization by MPER and 
other interface bnAbs [84]. Thus highlighting a reoccur-
ring theme in the isolation and characterization bnAbs, 
namely that combining a range of specificities [85] has 
great potential for therapeutic applications and vaccine 
development.
Insights into HIV Env: all bnAb epitopes
Combining the knowledge generated by the extensive 
array of bnAbs identified to date also provides important 
insights into HIV Env biology and new tools with which 
to evaluate immune responses against HIV. This is most 
clearly exemplified by the generation and validation of 
highly defined panels of pseudoviruses and epitope spe-
cific mutant viruses [86–88]. These tools enable quanti-
fication of the level of neutralization breadth across large 
cohorts and rapid detection of bnAb specificities within 
polyclonal serum samples [89]. These mapping tools 
have the potential to not only identify a larger number 
of individuals with broadly neutralizing sera but also to 
facilitate detection of low levels of activity or similar spe-
cificities in immunization studies. This in turn may help 
in the stepwise development of HIV Env vaccine candi-
dates. Moreover, the knowledge garnered from the exten-
sive study of bnAbs allows a more exacting investigation 
of host-virus specific immune responses during chronic 
infection. This in turn may be able to support work 
towards personalized immunotherapeutic approaches 
for HIV. Crucially the study of HIV bnAbs over the last 
decade has comprised a combination of epitope-focused 
and open-ended antibody discovery. This has facili-
tated highly detailed studies of how the particular bnAb 
classes function alongside the identification of new bnAb 
epitopes leading to insights into the fundamental biology 
of Env and the HIV entry process.
Why continue to study bnAbs against HIV?
A reoccurring theme throughout the study of HIV bnAbs 
during the last 10  years is that new epitopes are often 
discovered, despite earlier comprehensive studies [90, 
91]. This is exemplified by the identification of the inter-
face bnAbs [67, 76, 80] and the more recent description 
of interface bnAbs that use the fusion peptide to neu-
tralize virus [82, 83]. One of the most recent example of 
the identification of new epitopes is the description of a 
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single antibody, VRC-PG05, which recognizes a region 
on gp120 known as the silent face, comprising a dense 
N-linked glycan patch thought previously to be resistant 
to neutralizing antibodies [92]. VRC-PG05 binds directly 
to this “silent” glycan patch to neutralizes around 30% 
of viruses tested [93]. Intriguingly, electron microscopy 
studies suggest that only two copies of the antibody bind 
a single trimer, thus there is space for one CD4 molecule 
also to bind, leading the authors to state that VRC-PG05 
does not prevent CD4 binding to Env. Instead they pro-
pose that this antibody neutralizes viruses by impeding 
the conformational changes that allow CD4 to bind all 
three of its binding sites on Env and promote viral fusion 
[93].
In addition to the identification of new bnAb epitopes, 
continuing to isolate and characterize bnAbs can high-
light the differences between bnAbs in each class [21]. 
This in turn can lead to greater understanding of why it is 
challenging to induce such antibodies by immunization. 
In particular, the study of bnAb families or lineage stud-
ies have been highly informative. Early work in this area 
highlighted that predicted unmutated common ancestors 
(UCA) or inferred germ line (iGL) versions of most HIV 
bnAbs do not bind to Env with higher affinity [94, 95] 
and has led to concerted efforts to improve Env interac-
tions with putative bnAb precursors. UCA/iGL binding 
to Env has only been observed in two distinct situations. 
Firstly, where precise recapitulation of the eliciting viral 
strain is possible [88, 96]. Secondly, where a large part of 
the paratope is formed by an exceptionally long CDRH3 
region and thus present prior to affinity maturation [61]. 
Importantly, these long CDRH3 antibodies are rare in 
human B cell repertoires posing a challenge for expan-
sion upon immunization [97]. Characterization of early 
members of bnAb families has also been highly informa-
tive. Particularly when neutralization breadth is observed 
with antibodies of a similar level of affinity maturation 
(~ 10% somatic hypermutation) to those commonly elic-
ited by vaccination [36]. Furthermore, combining bnAb 
lineage studies with viral phylogenetics has begun to 
show how epitope diversification may lead to the devel-
opment of breath. Notably in one case due to partial viral 
neutralization escape over a prolonged period result-
ing in an expanded time window for bnAb maturation 
to occur [98]. Moreover, studying the ontology of bnAb 
families has illustrated that these rare antibodies are part 
of a larger Env-specific antibody repertoire within HIV-
positive individuals. Firstly, there was the description of a 
helper lineage that exerted selection pressure on the viral 
quasi species to drive it to form the epitope for an emerg-
ing bnAb family [99]. More recently, it has been reported 
that strain-specific neutralizing antibodies and bnAbs 
can function in parallel to limit escape by viral mutation 
and by doing so enhance the exposure of a bnAb epitope 
[100]. However, to date there has been minimal investi-
gation role of non-neutralizing antibodies in bnAb-pro-
ducing individuals, despite recent observations that such 
antibodies can alter HIV infection in humanized mice 
[101].
Another important reason to continue searching and 
characterizing bnAbs is that this work advances the abil-
ity of the field to analyze post-immunization responses. 
Limited progress has been made in inducing bnAbs by 
immunization, except in transgenic mice and animals 
with aberrantly structured antibodies [38, 102–104]. 
However, the panel of bnAbs available have allowed 
refinement of new immunogens to increase bnAb affin-
ity and limit binding to non-neutralizing epitopes [70, 
71, 74, 105]. Moreover, comparing the binding of neu-
tralizing mAbs isolated post-immunization to those of 
bnAbs has provided much greater understanding of why 
breadth has not been induced [65]. Furthermore, the 
wealth of knowledge generated on different bnAbs and 
their family members has also enabled the application of 
computational modeling approaches to the problems of 
how to induce these antibodies. This has recently been 
attempted in terms of the dynamics of germinal centers 
[106], the fitness landscape of Env [107] and the muta-
bility of antibodies [108]. However, importantly, predic-
tions based on these computational approaches require 
experimental validation. Already this has been attempted 
with earlier theoretical work focused on understanding 
the likelihood of bnAb precursor activation and clonal 
expansion. This was achieved by altering the frequency 
of bnAb precursors present in a transgenic mouse model 
[109]. Strikingly, this study revealed that both a threshold 
frequency and affinity are required for bnAb precursors 
to expand during an in vivo immunization [109].
Studying HIV bnAbs has also contributed to greater 
understanding of the basic rules underpinning the devel-
opment of antibodies and concurrent immunology. For 
example, isolation of bnAbs has highlighted that anti-
bodies raised in infants can be highly functional with-
out extensive hypermutation [110]. In addition, analysis 
of the B cell repertoires in bnAb-producing individu-
als has highlighted that different bnAb family members 
are found in altered proportions in peripheral and bone 
marrow compartments [56]. Furthermore, consideration 
of the multiple bnAbs isolated to date, and in particu-
lar bnAb B cell ontogeny studies have led to speculation 
about what the limits to B cell affinity maturation are 
and whether it is even possible to drive such extensive 
mutation by vaccination [111]. This has coincided with 
increased investigation into the virological and inflam-
matory profiles associated to the development of HIV 
bnAb-like activity [112, 113] and the complex nature of 
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the relationship between escape virus populations and 
antibodies in vivo [114, 115].
How can we use bnAbs against HIV?
An alternative consideration to what we can learn from 
bnAbs is how can we practically use the expanding array 
of bnAbs? That bnAbs can protect animals from experi-
mental challenge is one of the main pieces of evidence, 
which originally suggested that vaccines that can induce 
such antibodies would be protective. However, given 
the difficulties of inducing bnAbs by immunization, a 
reasonable short-cut for many is to deliver well charac-
terized bnAbs directly as either therapy or in a prophy-
lactic setting. Both the use of passive antibody infusions 
and vectored-antibody prophylaxis are being pursued 
with HIV bnAbs as reviewed extensively elsewhere [116, 
117]. These approaches are evaluating the usefulness 
not only of naturally occurring bnAbs but also compos-
ite forms including bi- and tri-specific engineered anti-
bodies that target multiple bnAb epitopes. Recent key 
bnAb studies in animal models and HIV-positive humans 
(Table  1) have highlighted the potential for bnAbs to 
protect from infection [118], to delay viral re-bound 
following anti-retroviral treatment cessation [119], to 
maintain viral supression [120] and to act as an adjunct 
to host immune-mediated control of virus [121]. Impor-
tantly, how and when these approaches can be integrated 
with current standards of care for patients remains to be 
clarified. There is growing interest in utilizing bnAbs in 
immunotherapeutic interventions aimed at curing infec-
tion as reviewed elsewhere [122, 123]. However, a recent 
observation, that super infection occurred in the pres-
ence of passively infused bnAb in an animal model [124], 
highlights the need for caution. Moreover, this work illus-
trates the need for a greater understanding of how bnAbs 
function and crucially how they impact ongoing infection 
in the infected individuals in which they develop. In turn, 
this supports the continued isolation and study of bnAbs.
In conclusion, the study of HIV bnAbs since 2009 has 
generated a huge body of knowlege as to how antibod-
ies can overcome the inherent obstacles in targeting a 
highly variable pathogen with a conformational variable 
surface protein, such as HIV. Primarily, this is achieved 
by bnAbs binding to regions the virus cannot alter with-
out drastically limiting itself. These regions include not 
only highly conserved amino acids at the receptor bind-
ing site but also to contacts needed to maintain envelope 
protein trimerisation. Moreover, bnAbs directly bind to 
the N-linked glycans that cover Env and actually facilitate 
evasion of less effective antibodies. The bnAbs identi-
fied are now being advanced to potential clinical applica-
tions but there remains much to learn by continuing to 
search for new bnAbs and in studying the processes by 
which they develop. Particularly, there is a need to under-
stand more clearly the development of BnAbs in the con-
text of the wider HIV specific antibody repertoire in the 
patients that produce them. It will be important to inves-
tigate the relative abundance of bnAbs within the anti-
body repertoire of the host, and the impact this has on 
their development in vivo. This in turn will suggest ways 
we can attempt to mimic bnAb generation by vaccina-
tion. Moreover, continued understanding of the varying 
ways in which bnAbs can bind their epitopes, in particu-
lar greater knowledge of any mechanistic limitations, will 
provide much needed insight into the therapeutic poten-
tial of bnAbs.
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